DDD vs XMTR: How DDD and Xometry Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DDD and XMTR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DDD and XMTR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

3D Systems Corporation is one of the original additive manufacturing companies, offering a broad portfolio of 3D printers, print materials, software, and on-demand manufacturing services. It reports in two segments. Healthcare Solutions covers dental, medical devices, and regenerative technologies like bioprinting, and in Q1 2026 grew about 21% year over year (roughly $50 million) on strength in Dental and Med Tech, each up over 20%. Industrial Solutions serves aerospace, defense, and general manufacturing and grew more modestly (roughly $45 million). Total Q1 2026 revenue was about $95.5 million, up ~1% reported but ~11% excluding divestitures, and healthcare has grown to a scale that now rivals the industrial business.

Full DDD guide

Xometry operates an online marketplace for custom manufacturing, matching buyers who upload a CAD file with a network of independent machine shops and fabricators, and using its own pricing engine to quote instantly.

Full XMTR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DDD drivers: Healthcare as the growth engine; Margin recovery and cost discipline.
• XMTR drivers: Marketplace economics; Data advantage compounds.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is that 3D Systems is a small, not-yet-consistently-profitable turnaround, so the thesis depends on execution that has not been fully proven. For XMTR, marketplace gross margins are structurally lower than a manufacturer's because Xometry pays the supplier for the work.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DDD if you believe its drivers more; XMTR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DDD and XMTR guides.

DDD. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because 3D Systems is not consistently GAAP-profitable, traditional earnings multiples are not very meaningful, and the stock trades more on revenue growth, margin trajectory, and cash burn than on a stable P/E. As a low-priced small cap it can be volatile and sensitive to a single quarter. Treat this as a turnaround valuation, where the key is whether improving margins and healthcare growth translate into durable free cash flow.

XMTR. Xometry is a marketplace rather than a manufacturer, so judge it on take rate, supplier retention and the trajectory toward profitability rather than on factory utilisation. Verify current figures.

Headline figures (approximate, Jul 2026): DDD shows revenue (q1 2026) ~$95.5 million, up ~1% reported (or ~11% excluding divestitures) year over year, segment mix Healthcare ~$50 million (up ~21%) roughly matched Industrial ~$45 million, gross margin (q1 2026, non-gaap) ~36%, up from ~30% a year earlier on richer product mix, profitability GAAP EPS loss narrowed to ~$(0.03); adjusted EBITDA slightly positive (~$2 million); XMTR shows business model Asset-light manufacturing marketplace with instant quoting, key metrics Take rate, active buyers, supplier network size, capital intensity Low, since production is outsourced to the network, profitability Has prioritised growth; verify the latest quarter.

DDD and XMTR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DDD and XMTR exposure against your real portfolio. It is not an investment adviser.